Ibrance (palbociclib) is set to face patent expiry in 2027 [1]. This expiry date marks a significant point for the drug, as it opens the door for generic competition [2].
When does Ibrance exclusivity expire?
The primary patents for Ibrance are expected to expire in 2027 [1]. However, the exact date can vary based on different patent types and any potential extensions or challenges [3]. DrugPatentWatch.com tracks these patent expiries and potential market entry dates for generics [1].
What happens after Ibrance patent expiry?
Following patent expiry, generic versions of Ibrance can enter the market [2]. This typically leads to a significant decrease in drug prices due to competition [4]. The availability of generics can improve patient access to treatment [5].
Can biosimilars enter before patent expiry?
Ibrance is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply; rather, "generic" versions are relevant [6]. Generic entry is primarily governed by patent expiry dates and regulatory approval processes [2].
What are the risks associated with Ibrance patent expiry?
For the originator company, the primary risk is a substantial loss of market share and revenue once generic competitors launch [2][4]. For patients and healthcare systems, the risk is less about the expiry itself and more about ensuring timely access to affordable generic alternatives and maintaining drug quality [5].
What is the current status of Ibrance patent litigation?
Patent litigation is common for high-value drugs like Ibrance. Companies often challenge existing patents to gain earlier market entry for their generic products [7]. Information on specific ongoing litigation or challenges for Ibrance patents can be found through specialized patent tracking services [1][7].
How does Ibrance compare to other breast cancer treatments?
Ibrance is a CDK4/6 inhibitor used in combination with endocrine therapy for certain types of advanced or metastatic breast cancer, specifically HR-positive, HER2-negative breast cancer [8]. It is one of several CDK4/6 inhibitors available, alongside drugs like Verzenio (abemaciclib) and Kisqali (ribociclib), each with their own efficacy and safety profiles [9].
What are the side effects of Ibrance?
Common side effects of Ibrance include neutropenia, fatigue, nausea, diarrhea, anemia, and hair loss [8]. Patients are advised to discuss potential side effects with their healthcare provider.
Who makes Ibrance and its generic versions?
Ibrance is manufactured by Pfizer [8]. Once patents expire, other pharmaceutical companies will be able to produce and market generic versions of palbociclib, provided they receive regulatory approval [2].
Sources:
[1] DrugPatentWatch.com
[2] https://drugpatentwatch.com/about-drug-patents/
[3] https://drugpatentwatch.com/blog/drug-patent-cliff-what-it-means-for-pharma-and-patients/
[4] https://drugpatentwatch.com/blog/understanding-drug-pricing-after-patent-expiration/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7784342/
[6] https://www.fda.gov/drugs/generic-drugs/what-biosimilar-and-interchangeable-biological-product
[7] https://drugpatentwatch.com/blog/patent-litigation-challenges-and-strategies-in-pharma/
[8] https://www.pfizer.com/products/product-detail/ibrance
[9] https://www.nejm.org/doi/full/10.1056/NEJMoa1814003